Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Thymus Neoplasms × Everolimus × Endocrine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 31 Carcinoma, Neuroendocrine 10 Carcinoid Tumor 8 Neoplasms 6 Adenoma, Islet Cell 5 Carcinoma, Renal Cell 4 Carcinoma, Medullary 4 Carcinoma, Islet Cell 4 Somatostatinoma 3 Pheochromocytoma 3 Neoplasm Metastasis 3 Insulinoma 3 Glucagonoma 3 Carcinoma 3 Thyroid Neoplasms 2 Thyroid Carcinoma, Anaplastic 2 Thyroid Cancer, Papillary 2 Paraganglioma 2 Neuroectodermal Tumors, Primitive 2 Liver Neoplasms 2 Head and Neck Neoplasms 2 Gastro-enteropancreatic neuroendocrine tumor 2 Gastrinoma 2 Carcinoma, Non-Small-Cell Lung 2 Carcinoma, Merkel Cell 2 Carcinoma, Hepatocellular 2 Adenocarcinoma, Follicular 2 von Hippel-Lindau Disease 1 Zollinger-Ellison Syndrome 1 Tuberous Sclerosis 1

Interventions

Radiotherapy 1 Radiation 1 Proton Therapy 1 Magnetic Resonance Spectroscopy 1 Fluorodeoxyglucose F18 1 FAPI-46 1 Everolimus 1 Blood Specimen Collection 1 177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05918302 2026-03-06

LEVEL

Grupo Espanol de Tumores Neuroendocrinos

Phase 3 Recruiting

Thymus Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡